Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03680573 · ClinicalTrials.gov registry record · Phase 1

The Effect of Antioxidants on Skin Blood Flow-BH4

A Phase 1 study, sponsored by The University of Texas at Arlington.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target

NCT03680573 is a Phase 1 study that has completed, run by The University of Texas at Arlington. The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03680573, a Phase 1 study, has completed, sponsored by The University of Texas at Arlington.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target

Study Summary

The goal of this study is to examine possible mechanisms of heightened vasoconstriction in Black/African American men and women as possible links to the elevated prevalence of cardiovascular dysfunction and disease. The main targets in this study are sources of oxidative stress

Interventions

  • DRUG Allopurinol
  • DRUG BH4
  • DRUG NG Nitro L Arginine Methyl Ester
  • DRUG Apocynin
  • DRUG Control: Lacated Ringers

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2018-01-08
Est. Completion 2018-05-05
Phase Phase 1

What the Registry Record Tells You About NCT03680573

The ClinicalTrials.gov registry entry for NCT03680573 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas at Arlington, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Allopurinol is the first listed.

NCT03680573 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03680573 about?

NCT03680573 is a clinical study titled "The Effect of Antioxidants on Skin Blood Flow-BH4". The goal of this study is to examine possible mechanisms of heightened vasoconstriction in Black/African American men and women as possible links to the elevated prevalence of cardiovascular dysfunction and disease. The main targets in this study are sources of oxidative stress

What is the current status of trial NCT03680573?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-01-08. Estimated completion is 2018-05-05.

What interventions are being tested in trial NCT03680573?

The interventions under investigation include: Allopurinol (DRUG), BH4 (DRUG), NG Nitro L Arginine Methyl Ester (DRUG), Apocynin (DRUG), Control: Lacated Ringers (DRUG).

Who is sponsoring clinical trial NCT03680573?

This trial is sponsored by The University of Texas at Arlington, which has 32 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.